Screening for diabetes

The prevalence of type 2 diabetes is rapidly increasing. A strong rationale exists for identifying asymptomatic individuals who are at high risk or are likely to have diabetes. Screening programs may provide a conduit through which diabetes intervention may be targeted towards those who might benefi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pathology 2012-02, Vol.44 (2), p.110-114
Hauptverfasser: Backholer, K., Chen, L., Shaw, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 114
container_issue 2
container_start_page 110
container_title Pathology
container_volume 44
creator Backholer, K.
Chen, L.
Shaw, J.
description The prevalence of type 2 diabetes is rapidly increasing. A strong rationale exists for identifying asymptomatic individuals who are at high risk or are likely to have diabetes. Screening programs may provide a conduit through which diabetes intervention may be targeted towards those who might benefit most. Diabetes screening could lessen disease burden in two ways. Firstly, by identifying people with undiagnosed diabetes, the burden of diabetes complications could be lessened through appropriate management of the condition. Secondly, by indentifying people at high risk of developing diabetes, and entering these people into diabetes prevention programs, the number of people with diabetes could be reduced. Screening for diabetes should ideally involve a non-invasive risk assessment followed by blood testing for those found to be at high risk. It should be noted that conclusive randomised controlled trial data to support the long-term health and economic impact of screening programs is lacking. The answers surrounding who and how we should screen for diabetes and the associated long term benefits will continue to evolve as the evidence base builds. As the use of screening for diabetes builds in popularity, it is essential that health care systems are sufficiently equipped to effectively manage the newly identified high risk and prevalent cases of type 2 diabetes.
doi_str_mv 10.1097/PAT.0b013e32834e8e12
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920227740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S003130251632579X</els_id><sourcerecordid>920227740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-93a3f2cb6d4300973743e12723051997a29fe4d30820ef737ce13b0284625ff83</originalsourceid><addsrcrecordid>eNp9kM1LAzEQxYMotlavnkR687R1ksnuJhehFL-goGA9h93sRCLtbk22Qv97I60ePDiXOczvzbx5jF1wmHDQ5fXzdDGBGjgSCoWSFHFxwIZcFnmGGvkhGwIgzxBEPmAnMb4DgFRKHbOBSKVEjkN2_mIDUevbt7HrwrjxVU09xVN25KplpLN9H7HXu9vF7CGbP90_zqbzzGLB-0xjhU7YumgkQjKFpcRkoxQIOde6rIR2JBsEJYBcGlviWINQshC5cwpH7Gq3dx26jw3F3qx8tLRcVi11m2i0ACHKUkIi5Y60oYsxkDPr4FdV2BoO5jsQkwIxfwNJssv9gU29ouZX9JNAAm52AKU3Pz0FE62n1lLjA9neNJ3__8IXFt9tnw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>920227740</pqid></control><display><type>article</type><title>Screening for diabetes</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Backholer, K. ; Chen, L. ; Shaw, J.</creator><creatorcontrib>Backholer, K. ; Chen, L. ; Shaw, J.</creatorcontrib><description>The prevalence of type 2 diabetes is rapidly increasing. A strong rationale exists for identifying asymptomatic individuals who are at high risk or are likely to have diabetes. Screening programs may provide a conduit through which diabetes intervention may be targeted towards those who might benefit most. Diabetes screening could lessen disease burden in two ways. Firstly, by identifying people with undiagnosed diabetes, the burden of diabetes complications could be lessened through appropriate management of the condition. Secondly, by indentifying people at high risk of developing diabetes, and entering these people into diabetes prevention programs, the number of people with diabetes could be reduced. Screening for diabetes should ideally involve a non-invasive risk assessment followed by blood testing for those found to be at high risk. It should be noted that conclusive randomised controlled trial data to support the long-term health and economic impact of screening programs is lacking. The answers surrounding who and how we should screen for diabetes and the associated long term benefits will continue to evolve as the evidence base builds. As the use of screening for diabetes builds in popularity, it is essential that health care systems are sufficiently equipped to effectively manage the newly identified high risk and prevalent cases of type 2 diabetes.</description><identifier>ISSN: 0031-3025</identifier><identifier>EISSN: 1465-3931</identifier><identifier>DOI: 10.1097/PAT.0b013e32834e8e12</identifier><identifier>PMID: 22228253</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>AUSDRISK ; Cost-Benefit Analysis ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - economics ; Diabetes Mellitus, Type 2 - epidemiology ; Early Diagnosis ; Humans ; impaired glucose tolerance ; Mass Screening - economics ; Mass Screening - methods ; Prevalence ; risk prediction equation ; risk prediction tool ; screening ; type 2 diabetes</subject><ispartof>Pathology, 2012-02, Vol.44 (2), p.110-114</ispartof><rights>2012 Royal College of Pathologists of Australasia</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-93a3f2cb6d4300973743e12723051997a29fe4d30820ef737ce13b0284625ff83</citedby><cites>FETCH-LOGICAL-c361t-93a3f2cb6d4300973743e12723051997a29fe4d30820ef737ce13b0284625ff83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22228253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Backholer, K.</creatorcontrib><creatorcontrib>Chen, L.</creatorcontrib><creatorcontrib>Shaw, J.</creatorcontrib><title>Screening for diabetes</title><title>Pathology</title><addtitle>Pathology</addtitle><description>The prevalence of type 2 diabetes is rapidly increasing. A strong rationale exists for identifying asymptomatic individuals who are at high risk or are likely to have diabetes. Screening programs may provide a conduit through which diabetes intervention may be targeted towards those who might benefit most. Diabetes screening could lessen disease burden in two ways. Firstly, by identifying people with undiagnosed diabetes, the burden of diabetes complications could be lessened through appropriate management of the condition. Secondly, by indentifying people at high risk of developing diabetes, and entering these people into diabetes prevention programs, the number of people with diabetes could be reduced. Screening for diabetes should ideally involve a non-invasive risk assessment followed by blood testing for those found to be at high risk. It should be noted that conclusive randomised controlled trial data to support the long-term health and economic impact of screening programs is lacking. The answers surrounding who and how we should screen for diabetes and the associated long term benefits will continue to evolve as the evidence base builds. As the use of screening for diabetes builds in popularity, it is essential that health care systems are sufficiently equipped to effectively manage the newly identified high risk and prevalent cases of type 2 diabetes.</description><subject>AUSDRISK</subject><subject>Cost-Benefit Analysis</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - economics</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Early Diagnosis</subject><subject>Humans</subject><subject>impaired glucose tolerance</subject><subject>Mass Screening - economics</subject><subject>Mass Screening - methods</subject><subject>Prevalence</subject><subject>risk prediction equation</subject><subject>risk prediction tool</subject><subject>screening</subject><subject>type 2 diabetes</subject><issn>0031-3025</issn><issn>1465-3931</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1LAzEQxYMotlavnkR687R1ksnuJhehFL-goGA9h93sRCLtbk22Qv97I60ePDiXOczvzbx5jF1wmHDQ5fXzdDGBGjgSCoWSFHFxwIZcFnmGGvkhGwIgzxBEPmAnMb4DgFRKHbOBSKVEjkN2_mIDUevbt7HrwrjxVU09xVN25KplpLN9H7HXu9vF7CGbP90_zqbzzGLB-0xjhU7YumgkQjKFpcRkoxQIOde6rIR2JBsEJYBcGlviWINQshC5cwpH7Gq3dx26jw3F3qx8tLRcVi11m2i0ACHKUkIi5Y60oYsxkDPr4FdV2BoO5jsQkwIxfwNJssv9gU29ouZX9JNAAm52AKU3Pz0FE62n1lLjA9neNJ3__8IXFt9tnw</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Backholer, K.</creator><creator>Chen, L.</creator><creator>Shaw, J.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Screening for diabetes</title><author>Backholer, K. ; Chen, L. ; Shaw, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-93a3f2cb6d4300973743e12723051997a29fe4d30820ef737ce13b0284625ff83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>AUSDRISK</topic><topic>Cost-Benefit Analysis</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - economics</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Early Diagnosis</topic><topic>Humans</topic><topic>impaired glucose tolerance</topic><topic>Mass Screening - economics</topic><topic>Mass Screening - methods</topic><topic>Prevalence</topic><topic>risk prediction equation</topic><topic>risk prediction tool</topic><topic>screening</topic><topic>type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Backholer, K.</creatorcontrib><creatorcontrib>Chen, L.</creatorcontrib><creatorcontrib>Shaw, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Backholer, K.</au><au>Chen, L.</au><au>Shaw, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening for diabetes</atitle><jtitle>Pathology</jtitle><addtitle>Pathology</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>44</volume><issue>2</issue><spage>110</spage><epage>114</epage><pages>110-114</pages><issn>0031-3025</issn><eissn>1465-3931</eissn><abstract>The prevalence of type 2 diabetes is rapidly increasing. A strong rationale exists for identifying asymptomatic individuals who are at high risk or are likely to have diabetes. Screening programs may provide a conduit through which diabetes intervention may be targeted towards those who might benefit most. Diabetes screening could lessen disease burden in two ways. Firstly, by identifying people with undiagnosed diabetes, the burden of diabetes complications could be lessened through appropriate management of the condition. Secondly, by indentifying people at high risk of developing diabetes, and entering these people into diabetes prevention programs, the number of people with diabetes could be reduced. Screening for diabetes should ideally involve a non-invasive risk assessment followed by blood testing for those found to be at high risk. It should be noted that conclusive randomised controlled trial data to support the long-term health and economic impact of screening programs is lacking. The answers surrounding who and how we should screen for diabetes and the associated long term benefits will continue to evolve as the evidence base builds. As the use of screening for diabetes builds in popularity, it is essential that health care systems are sufficiently equipped to effectively manage the newly identified high risk and prevalent cases of type 2 diabetes.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>22228253</pmid><doi>10.1097/PAT.0b013e32834e8e12</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-3025
ispartof Pathology, 2012-02, Vol.44 (2), p.110-114
issn 0031-3025
1465-3931
language eng
recordid cdi_proquest_miscellaneous_920227740
source MEDLINE; Alma/SFX Local Collection
subjects AUSDRISK
Cost-Benefit Analysis
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - economics
Diabetes Mellitus, Type 2 - epidemiology
Early Diagnosis
Humans
impaired glucose tolerance
Mass Screening - economics
Mass Screening - methods
Prevalence
risk prediction equation
risk prediction tool
screening
type 2 diabetes
title Screening for diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T23%3A47%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening%20for%20diabetes&rft.jtitle=Pathology&rft.au=Backholer,%20K.&rft.date=2012-02-01&rft.volume=44&rft.issue=2&rft.spage=110&rft.epage=114&rft.pages=110-114&rft.issn=0031-3025&rft.eissn=1465-3931&rft_id=info:doi/10.1097/PAT.0b013e32834e8e12&rft_dat=%3Cproquest_cross%3E920227740%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=920227740&rft_id=info:pmid/22228253&rft_els_id=S003130251632579X&rfr_iscdi=true